Press
 

Company press release

 

Proteo, Inc./Proteo Biotech AG: Orphan Drug Designation for Elafin in the Treatment of Oesophagus Carcinoma

Irvine, CA – Kiel, February 4, 2010 – Proteo, Inc. (OTCBB: PTEO; WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG announced today:

Following the recommendation of the European Medicines Agency EMEA, the European Commission has granted Orphan Drug Designation for the protease inhibitor Elafin, developed by Proteo, to be used in the treatment of oesophagus carcinoma. Orphan Drug Designation of the European Commission assures exclusive marketing rights for the treatment of this disease within the European Union for a period of up to ten years after receiving market approval. Additionally, registration as an Orphan Drug enables accelerated marketing approval in all member states of the European Union.

In a Phase I clinical trial it was demonstrated that Elafin was very well tolerated. The substance is currently under investigation in a Phase II clinical trial on patients undergoing oesophagectomy for the treatment of oesophagus carcinoma.

About Proteo

The company researches, develops and markets compounds for biological and medical research as well as for use as pharmaceuticals. The main focus is on anti-inflammatory drugs, in particular on the human elastase inhibitor Elafin. Proteo intends to out-license selected indications and to establish international strategic alliances in order to open up new fields of application and for marketing (www.proteo.de).

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward looking statements and risks and uncertainties involved are further qualified by other factors including, but not limited to those set forth in the company’s Form 10-K filing and other filings with the United States Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

Contact

Barbara Kahlke, Ph.D.
Proteo Biotech AG
Am Kiel-Kanal 44
D-24106 Kiel

Email: info@proteo.de
Telephone: +49 431 8888-462
Fax: +49 431 8888-463

https://proteo.de/pages/12/press-releases/2010/02/04/orphan-drug-designation-for-elafin-in-the-treatment-of-oesophagus-carcinoma/ – printed on 2018-11-16 8:26:24